Zhongzhi Pharmaceutical Holdings (HKSE:03737) Risk Assessment

View and export this data going back to 2015. Start your Free Trial

What is Zhongzhi Pharmaceutical Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Zhongzhi Pharmaceutical Holdings is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Zhongzhi Pharmaceutical Holdings's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Zhongzhi Pharmaceutical Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zhongzhi Pharmaceutical Holdings's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhongzhi Pharmaceutical Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Zhongzhi Pharmaceutical Holdings's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Zhongzhi Pharmaceutical Holdings (HKSE:03737) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Zhongzhi Pharmaceutical Holdings Risk Assessment Related Terms

Thank you for viewing the detailed overview of Zhongzhi Pharmaceutical Holdings's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhongzhi Pharmaceutical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhongzhi Pharmaceutical Holdings Ltd (HKSE:03737) » Definitions » Risk Assessment

Traded in Other Exchanges

N/A

Address

No. 3 Kangtai Road South, Torch Development Zone, Guangdong Province, Zhongshan, CHN

Website

https://www.zeus.cn

Zhongzhi Pharmaceutical Holdings Ltd is engaged in the business of manufacturing and selling pharmaceutical products. The group's operations can be divided into three segments, namely Pharmaceutical manufacturing, Operation of chain pharmacies, and Operation of online pharmacies in Zhongshan in the Guangdong province, the PRC. In the Pharmaceutical manufacturing segment, the company is engaged in the research and development, manufacturing and sale of Chinese patent medicines. In the Operation of chain pharmacies segment, the firm operates chain pharmacies in Zhongshan under the brand Zeus for the sale of pharmaceutical products. The Operation of online pharmacies segment sells medicines online. It derives a majority of its revenue from the PRC.

Executives

Jiang Li Xia	2202 Interest of your spouse
Lai Zhi Tian	2201 Interest of corporation controlled by you
Crystal Talent Investment Group Limited	2101 Beneficial owner
Cheng Jin Le	2201 Interest of corporation controlled by you
Advance Keypath Global Investment Limited	2101 Beneficial owner
Novich Positioning Investment (cayman) Limited	2201 Interest of corporation controlled by you
Novich Positioning Investment Limited Partnership	2101 Beneficial owner

Zhongzhi Pharmaceutical Holdings Headlines

No Headlines